NCT01672775 (Clinical Trial/ AGS-16C3F/ AGS-16M8F/ AGS 16C3F)

Study Title
A Study to Assess the Safety, Pharmacokinetics and Effectiveness of AGS-16C3F Monotherapy in Subjects With Renal Cell Carcinoma (RCC) of Clear Cell or Papillary Histology (NCT01672775)

Trial Description
The purpose of this study is to evaluate the safety and pharmacokinetics and assess the immunogenicity and effectiveness of AGS-16C3F (also known as AGS-16M8F/ AGS 16C3F)  in subjects with renal cell cancer (RCC). This trial is sponsored by Agensys/Astellas Pharma. [1]

Study Data

  • Condition: Renal Cell Carcinoma
  • Interventions:
    • Drugs used in this trial
      • AGS-16C3F (AGS-16M8F/ AGS 16C3F)
  • Phase: I
  • Enrollment: 34
  • Start: July 2012
  • Estimated Completion: September 2015
  • Last verified: March 2015

Study Schematic

NCT01672775

Click here to Return to Drug map


Last Editorial review: August 28, 2017
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.